Skip to main
VCYT

Veracyte (VCYT) Stock Forecast & Price Target

Veracyte (VCYT) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 56%
Buy 22%
Hold 11%
Sell 11%
Strong Sell 0%

Bulls say

Veracyte is a genomic diagnostics company with a strong portfolio of tests for prostate, thyroid, breast, and bladder cancer. The recent acquisition of Convergent Genomics and C2i Genomics signals their commitment to expanding their offerings and cementing their position in the market. With a successful track record of revenue growth, strategic acquisitions, and a strong pipeline, Veracyte looks set to continue its upward trend, but risks such as competition and regulatory challenges should also be considered. Keep an eye on this stock as it could potentially reach $57 in a positive scenario.

Bears say

Veracyte is facing several key challenges that could limit its growth potential. These include the maturity of the thyroid testing market, reimbursement and payer concentration for its products, and competition in the genomic diagnostics space. Additionally, while the company's pipeline and recent launches offer upside potential, there is a risk of deceleration in core testing and penetration plateau for its flagship Decipher and Afirma tests. These factors, combined with the company's high valuation compared to its peers, contribute to a negative outlook for Veracyte's stock.

Veracyte (VCYT) has been analyzed by 9 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 22% recommend Buy, 11% suggest Holding, 11% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Veracyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Veracyte (VCYT) Forecast

Analysts have given Veracyte (VCYT) a Buy based on their latest research and market trends.

According to 9 analysts, Veracyte (VCYT) has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Veracyte (VCYT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.